AQST — Aquestive Therapeutics, Inc.

Summary of AQST Earnings Call (Q4 2025)

1. Key Financial Results and Metrics

• Q4 2025 Revenues: $13 million, up 10% from $11.9 million in Q4 2024, driven by increased manufacturer and supply revenue, particularly from Suboxone and ONDEEF.
• Full Year 2025 Revenues: $44.5 million, down from $57.6 million in 2024, primarily due to a one-time recognition of deferred revenue in 2024.
• Net Loss:
  • Q4 2025: $31.9 million ($0.26 per share), including one-time legal expenses, compared to a net loss of $17.1 million in Q4 2024.
  • Full Year 2025: $83.8 million ($0.78 per share), compared to $44.1 million in 2024.
• Cash Position: $121.2 million as of December 31, 2025, with a cash runway supporting upcoming NDA resubmission and pre-commercial activities.

2. Strategic Updates and Business Highlights

• ANNAFILM Development: The company is preparing for a Type A meeting with the FDA and plans to resubmit the NDA in Q3 2026. They are also expanding their clinical team and medical affairs organization to enhance outreach and education.
• Commercial Strategy: Plans to launch ANNAFILM with 75 sales representatives, 50% more than previously guided, to improve market penetration and coverage.
• Legal Matters: Successfully settled a long-standing defamation lawsuit, removing a distraction from business operations.
• Licensing Plans: Focus on out-licensing Libervant in the U.S. and ANNAFILM in Europe, with ongoing discussions with multiple parties.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected to be between $46 million and $50 million.
• Non-GAAP Adjusted EBITDA Loss: Projected to be between $30 million and $35 million.
• Cash Guidance: Anticipated to end 2026 with approximately $70 million, excluding additional proceeds from RTW or out-licensing transactions.

4. Bad News, Challenges, or Points of Concern

• Increased Losses: The company reported a significant increase in net losses due to rising selling, general, and administrative expenses, particularly legal fees.
• Market Competition: The allergy market is competitive, with existing products like auto-injectors dominating. The company faces pressure to establish market share for ANNAFILM.
• Regulatory Risks: The FDA's approval process remains uncertain, and the company must navigate potential modifications requested during the upcoming Type A meeting.

5. Notable Q&A Insights

• FDA Interaction: The Type A meeting with the FDA is expected to occur within 30 days, with the company seeking alignment on study designs.
• Sales Strategy: The decision to increase the sales force is based on the need for deeper market penetration and efficiency in reaching healthcare providers.
• DTC Marketing: The company plans to focus on direct sales efforts rather than direct-to-consumer advertising until they establish a market presence.
• Clinical Development: AQST-108's future development is linked to ANNAFILM's progress, with resources prioritized for ANNAFILM.

In summary, Aquestive Therapeutics is positioned for a pivotal year with the anticipated resubmission of ANNAFILM, despite facing increased losses and competitive pressures in the allergy treatment market. The company is optimistic about its strategic direction and financial outlook for 2026.